AN2 Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ANTX Nasdaq 2830 www.an2therapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AN2 Therapeutics, Inc.

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Nov 12th, 2025 2:01 pm
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) - Nov 10th, 2025 5:00 am
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference - Nov 6th, 2025 3:03 pm
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Aug 12th, 2025 2:01 pm
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease - Aug 12th, 2025 5:00 am
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease - Jul 23rd, 2025 5:00 am
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole - Jun 30th, 2025 5:00 am
Positive Signs As Multiple Insiders Buy AN2 Therapeutics Stock - Jun 28th, 2025 7:39 am
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference - May 29th, 2025 5:00 am
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights - May 13th, 2025 2:01 pm
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline - May 1st, 2025 2:00 pm
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference - Apr 30th, 2025 5:00 am
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation - Apr 7th, 2025 4:20 am
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights - Mar 25th, 2025 2:00 pm
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference - Mar 3rd, 2025 2:00 pm
Golden Sun Health Technology Group Leads 3 US Penny Stocks Worth Monitoring - Feb 25th, 2025 1:11 pm
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease - Feb 24th, 2025 5:00 am
AN2 Therapeutics to Participate at Upcoming Investor Conferences - Feb 20th, 2025 5:00 am
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Jan 29th, 2025 2:00 pm
Favourable Signals For AN2 Therapeutics: Numerous Insiders Acquired Stock - Jan 19th, 2025 5:18 am